Late Effects of Estrogen Deprivation in Breast Cancer
This video examines the late effects of estrogen deprivation in both younger and older breast cancer patients, including bone thinning, heart disease, and dementia.
Treatment with aromatase inhibitors exposes patients to late effects, including the risk of bone thinning, heart disease, and dementia.
In this video Ann Partridge, MD, MPH, of the Dana-Farber Cancer Institute in Boston, discusses how to monitor for and manage these late effects of estrogen deprivation in both younger and older breast cancer patients.
Giredestrant Combo Yields Positive PFS in Subgroups After CDK4/6i in ER+/HER2– Breast Cancer
December 13th 2025“The magnitude of clinical benefit was clinically meaningful and consistent, and was regardless of PIK3CA mutations or alterations in the PIK3CA pathway, duration of prior CDK4/6 inhibitors, including patients who progress within 6 to 12 months, and the choice of prior CDK4/6 inhibitors,” said Hope S. Rugo, MD.
